No profile data available.
Nuo Therapeutics, Inc. (AURX) is a healthcare company in the healthcare consumable products industry, based in Houston, United States, with about 10 full-time employees.
It reported revenue of $3.31 million for fiscal year 2025, up 142.7% from fiscal year 2024, and net income of -$2.51 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.77 million, up 152.6% from a year before. Its largest business segment, Product, brought in 93% of segment revenue in fiscal year 2025. Its market capitalization was $62.96 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States.
Nuo Therapeutics reported $3.31 million in revenue for fiscal year 2025, up 142.7% from $1.37 million in fiscal year 2024. In Q2 2026 revenue was $1.77 million.
Product, with $3.09 million or 93% of segment revenue in fiscal year 2025. Next: License (7%).
$62.96 million as of October 8, 2026.
Listed companies of a similar size in the same industry (healthcare consumable products) include MediWound Ltd. (MDWD), Jin Medical International Ltd. (ZJYL), Sanuwave Health, Inc. (SNWV), Cuprina Holdings (Cayman) Limited (CUPR).